COVID-19 heart damage may be limited in the medium-term

Embargoed until: Publicly released: 2024-08-29 04:00

Australia; International; VIC

Photo by Robina Weermeijer on Unsplash

People hospitalised with COVID-19 who have heart damage as a result can feel reassured that their heart injuries don't appear to get worse after they leave hospital, and some measures may improve over time, according to Australian and international research. The study, which looked at people who had not been vaccinated, found that after six months some measures of their heart health including scarring remained unchanged, while other measures such as inflammation and quality of life appeared to improve. The study also found that the rates of serious heart issues after leaving hospital, including acute coronary syndrome and death, were low overall.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research American College of Cardiology, Web page Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Editorial / Opinion American College of Cardiology, Web page Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Journal/
conference: JACC: Cardiovascular Imaging

Research:Paper

Organisation/s: Baker Heart and Diabetes Institute, Monash University, University College London, UK

Funder: This work was supported by NIHR (National Institute for Health and Care Research) and UK Research and Innovation (COV0254). West Yorkshire and Humber Clinical Research Network (CV070) funded the patient information leaflet translation. Dr Berry has received British Heart Foundation support (RE/18/6134217). Dr Artico received funding from the European Association of Cardiovascular Imaging (EACVI Research Grant App000073878). Dr McCann is funded by a NIHR Research Professorship (RP-2017-08-ST2-007). Dr Manisty is funded by a NIHR Clinician Scientist Award (CS-2015-15-003). Drs Ferreira, Piechnik, and Neubauer acknowledge the NIHR Oxford BRC for support of this study. Dr Bucciarelli-Ducci is in part supported by the NIHR Biomedical Research Centre at University Hospitals Bristol NHS (National Health Service) Foundation Trust and the University of Bristol. Additional support was provided by the NIHR Leicester Biomedical Research Centre and the NIHR Leeds Clinical Research Facility. Dr Dweck is supported by the British Heart Foundation (FS/ SCRF/21/32010). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care. Dr Moon has served on Advisory Boards for Sanofi and Genzyme. Dr Miller has served on Advisory Boards for Novartis, Boehringer Ingelheim and Lilly Alliance, and AstraZeneca; serves as an advisor for HAYA Therapeutics and PureTech Health; and has received research support from Amicus Therapeutics, Guerbet Laboratories Limited, Roche, and Univar Solutions B.V. Dr Bucciarelli- Ducci is the chief executive officer (part-time) of the Society for Magnetic Resonance. Dr Berry is employed by the University of Glasgow, which holds research and/or consultancy agreements with AstraZeneca, Abbott Vascular, Boehringer Ingelheim, GlaxoSmithKline, HeartFlow, Opsens, and Novartis

Media Contact/s

Contact details are only visible to registered journalists.